UY36006A - Construcciones de proteína uspa2 y usos de las mismas. - Google Patents
Construcciones de proteína uspa2 y usos de las mismas.Info
- Publication number
- UY36006A UY36006A UY0001036006A UY36006A UY36006A UY 36006 A UY36006 A UY 36006A UY 0001036006 A UY0001036006 A UY 0001036006A UY 36006 A UY36006 A UY 36006A UY 36006 A UY36006 A UY 36006A
- Authority
- UY
- Uruguay
- Prior art keywords
- uspa2
- same
- compositions
- immunogenic compositions
- uspa2 protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
- A61K39/1045—Moraxella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1217—Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1218—Acinetobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943909P | 2014-02-24 | 2014-02-24 | |
| US201461946937P | 2014-03-03 | 2014-03-03 | |
| US201461946932P | 2014-03-03 | 2014-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY36006A true UY36006A (es) | 2015-09-30 |
Family
ID=52629643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001036006A UY36006A (es) | 2014-02-24 | 2015-02-20 | Construcciones de proteína uspa2 y usos de las mismas. |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10040832B2 (enExample) |
| EP (2) | EP3498292B1 (enExample) |
| JP (1) | JP6585085B2 (enExample) |
| KR (1) | KR102515835B1 (enExample) |
| CN (2) | CN111499701A (enExample) |
| AU (1) | AU2015220369B2 (enExample) |
| BE (1) | BE1022345A9 (enExample) |
| BR (1) | BR112016019525B1 (enExample) |
| CA (1) | CA2939862C (enExample) |
| CY (2) | CY1121535T1 (enExample) |
| DK (2) | DK3110438T3 (enExample) |
| EA (1) | EA034352B1 (enExample) |
| ES (2) | ES2715674T3 (enExample) |
| HR (2) | HRP20211926T1 (enExample) |
| HU (2) | HUE042054T2 (enExample) |
| IL (1) | IL246994B (enExample) |
| LT (2) | LT3498292T (enExample) |
| ME (1) | ME03335B (enExample) |
| MX (1) | MX376079B (enExample) |
| PL (2) | PL3498292T3 (enExample) |
| PT (2) | PT3498292T (enExample) |
| RS (2) | RS62592B1 (enExample) |
| SG (1) | SG11201606272PA (enExample) |
| SI (2) | SI3110438T1 (enExample) |
| SM (2) | SMT201900166T1 (enExample) |
| TW (1) | TW201620927A (enExample) |
| UY (1) | UY36006A (enExample) |
| WO (1) | WO2015125118A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| EP3600391A1 (en) * | 2017-03-31 | 2020-02-05 | GlaxoSmithKline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| GB2600653B (en) | 2017-05-30 | 2022-11-02 | Glaxosmithkline Biologicals Sa | Novel methods |
| EP3641808A1 (en) * | 2017-08-14 | 2020-04-29 | GlaxoSmithKline Biologicals S.A. | Methods of boosting immune responses |
| BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
| GB201803692D0 (en) * | 2018-03-08 | 2018-04-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| EP3840770A1 (en) * | 2018-08-23 | 2021-06-30 | GlaxoSmithKline Biologicals SA | Immunogenic proteins and compositions |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| WO2020245207A1 (en) | 2019-06-05 | 2020-12-10 | Glaxosmithkline Biologicals Sa | Saponin purification |
| AU2020325645A1 (en) | 2019-08-05 | 2022-02-17 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| BR112021026775A2 (pt) | 2019-08-05 | 2022-05-10 | Glaxosmithkline Biologicals Sa | Processo para preparar uma composição que compreende um polipeptídeo de proteína d |
| EP4028771A1 (en) | 2019-09-11 | 2022-07-20 | GlaxoSmithKline Biologicals S.A. | Assay |
| US20240148849A1 (en) | 2021-02-22 | 2024-05-09 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and methods |
| EP4558170A1 (en) | 2022-07-19 | 2025-05-28 | GlaxoSmithKline Biologicals S.A. | Continuous process for vaccine production |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5776468A (en) | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP0948625B1 (en) * | 1996-12-20 | 2011-01-26 | The Board Of Regents, The University Of Texas System | Uspa1 and uspa2 antigens of moraxella catarrhalis |
| AU2001294750C1 (en) | 2000-09-26 | 2008-09-18 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| US6942802B2 (en) | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| ATE469915T1 (de) * | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| EA014352B1 (ru) * | 2005-08-10 | 2010-10-29 | Арне Форсгрен Аб | Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента |
| CN101243104B (zh) * | 2005-08-10 | 2012-07-18 | 阿恩·福斯格伦股份公司 | 卡他莫拉氏菌与上皮细胞、细胞外基质蛋白及补体系统的相互作用 |
| MY150105A (en) * | 2006-01-17 | 2013-11-29 | Forsgren Arne | A novel surface exposed haemophilus influenzae protein (protein e; pe) |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| SG194886A1 (en) * | 2011-05-11 | 2013-12-30 | Riesbeck Healthcare Sweden Ab | Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties |
| TW201620927A (zh) * | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
-
2015
- 2015-02-17 TW TW104105745A patent/TW201620927A/zh unknown
- 2015-02-20 BE BE20155094A patent/BE1022345A9/fr not_active IP Right Cessation
- 2015-02-20 EP EP18211544.4A patent/EP3498292B1/en active Active
- 2015-02-20 US US15/119,220 patent/US10040832B2/en active Active
- 2015-02-20 SI SI201530667T patent/SI3110438T1/sl unknown
- 2015-02-20 ME MEP-2019-54A patent/ME03335B/me unknown
- 2015-02-20 CN CN202010194047.1A patent/CN111499701A/zh active Pending
- 2015-02-20 BR BR112016019525-6A patent/BR112016019525B1/pt not_active IP Right Cessation
- 2015-02-20 UY UY0001036006A patent/UY36006A/es not_active Application Discontinuation
- 2015-02-20 ES ES15708341T patent/ES2715674T3/es active Active
- 2015-02-20 DK DK15708341.1T patent/DK3110438T3/en active
- 2015-02-20 PT PT182115444T patent/PT3498292T/pt unknown
- 2015-02-20 EA EA201691611A patent/EA034352B1/ru not_active IP Right Cessation
- 2015-02-20 PT PT15708341T patent/PT3110438T/pt unknown
- 2015-02-20 HR HRP20211926TT patent/HRP20211926T1/hr unknown
- 2015-02-20 SI SI201531759T patent/SI3498292T1/sl unknown
- 2015-02-20 JP JP2016570199A patent/JP6585085B2/ja not_active Expired - Fee Related
- 2015-02-20 SM SM20190166T patent/SMT201900166T1/it unknown
- 2015-02-20 LT LTEP18211544.4T patent/LT3498292T/lt unknown
- 2015-02-20 KR KR1020167022954A patent/KR102515835B1/ko active Active
- 2015-02-20 SG SG11201606272PA patent/SG11201606272PA/en unknown
- 2015-02-20 ES ES18211544T patent/ES2899300T3/es active Active
- 2015-02-20 AU AU2015220369A patent/AU2015220369B2/en not_active Ceased
- 2015-02-20 SM SM20210728T patent/SMT202100728T1/it unknown
- 2015-02-20 WO PCT/IB2015/051308 patent/WO2015125118A1/en not_active Ceased
- 2015-02-20 RS RS20211446A patent/RS62592B1/sr unknown
- 2015-02-20 PL PL18211544T patent/PL3498292T3/pl unknown
- 2015-02-20 HU HUE15708341A patent/HUE042054T2/hu unknown
- 2015-02-20 HU HUE18211544A patent/HUE057505T2/hu unknown
- 2015-02-20 HR HRP20190412TT patent/HRP20190412T1/hr unknown
- 2015-02-20 EP EP15708341.1A patent/EP3110438B1/en active Active
- 2015-02-20 RS RS20190297A patent/RS58451B1/sr unknown
- 2015-02-20 CA CA2939862A patent/CA2939862C/en active Active
- 2015-02-20 MX MX2016010954A patent/MX376079B/es active IP Right Grant
- 2015-02-20 DK DK18211544.4T patent/DK3498292T3/da active
- 2015-02-20 CN CN201580010155.6A patent/CN106061995A/zh active Pending
- 2015-02-20 PL PL15708341T patent/PL3110438T3/pl unknown
- 2015-02-20 LT LTEP15708341.1T patent/LT3110438T/lt unknown
-
2016
- 2016-07-28 IL IL246994A patent/IL246994B/en active IP Right Grant
-
2018
- 2018-06-29 US US16/023,164 patent/US10745449B2/en active Active
-
2019
- 2019-03-14 CY CY20191100307T patent/CY1121535T1/el unknown
-
2020
- 2020-06-29 US US16/914,750 patent/US10947280B2/en active Active
-
2021
- 2021-11-30 CY CY20211101038T patent/CY1124979T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY36006A (es) | Construcciones de proteína uspa2 y usos de las mismas. | |
| NI201800052A (es) | Anticuerpos que neutraliza el virus respiratorio sincitial humano | |
| DOP2013000235A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
| MX387985B (es) | Particulas tipo virus modificadas de cmv. | |
| MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
| EA201691348A1 (ru) | Однофлаконные вакцинные составы | |
| BR112018012873A2 (pt) | vacina de vírus zika | |
| WO2014113490A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| PT3096785T (pt) | Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas | |
| MX2015010783A (es) | Composicion de vacuna. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| AR102547A1 (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
| MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
| BR112014020025A8 (pt) | Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
| MX2016010838A (es) | Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9). | |
| MX381745B (es) | Vacunas de pestivirus para temblores congenitos. | |
| CL2019000705A1 (es) | Nuevos promotores. | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| WO2014121037A8 (en) | Hydroxylamine-terminated polysiloxane and methods of making and using the same | |
| AR099553A1 (es) | Construcciones de proteína uspa2 y usos de las mismas | |
| CL2013002782A1 (es) | Formulación inmunogénica para inducir la respuesta inmune en un sujeto que comprende una mezcla de bacterias no patógenas que expresan cada una un segmento hipervariable de la proteína m de diferentes streptococcus pyogenes; uso de la formulación para producir una vacuna; método para producir vacuna | |
| ECSP18039827A (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220610 |